Risk Factors Update Summary

• We incurred a net loss of $37 million during the year ended September 30, 2024, compared to $93 million in 2023. This significant change highlights worsening financial conditions.
• If ONCO defaults on the Promissory Notes, we may declare the full amount due, risking bankruptcy.
• We are currently ineligible to file new registration statements on Form S-3 until March 1, 2025, which may impair our ability to raise capital on favorable terms.
• Net revenues from sales of FC2 have declined significantly due to The Pill Club's Chapter 11 bankruptcy filing on April 18, 2023.
• We agreed to pay a total of $8.3 million to resolve a dispute with a supplier, impacting cash flow.
• We may not receive any additional payments from ONCO, including $10 million in installments and up to $80 million in milestone payments, impacting our financial stability.
• We have recorded an allowance for credit losses of $3.9 million as of September 30, 2024, due to receivables from The Pill Club.
• We may face significant consequences if our common stock is delisted from Nasdaq due to non-compliance with bid price requirements.
• Interim, preliminary, and topline data from our clinical trials may change, affecting investor confidence and stock volatility as results are subject to audit and verification procedures.
• Our federal net operating loss carryforwards increased from approximately $140 million to $164 million, affecting future tax obligations.
• We expect to incur significant expenditures over the next fiscal year, influenced by various factors including the complexity and timing of our development programs.